The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Girostan     tris(aziridin-1-yl)- sulfanylidene-phosphorane

Synonyms: Tespamin, thiotepa, TESPA, THIO-TEPA, NSC-6396, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of thiotepa


Psychiatry related information on thiotepa


High impact information on thiotepa


Chemical compound and disease context of thiotepa


Biological context of thiotepa


Anatomical context of thiotepa

  • The day +28 T cells were exclusively of donor origin in 14 of 17 patients who received TBI plus thiotepa plus Cy, but were mixed chimeric in 10 of 12 patients who received other conditioning regimens (P < .001) [21].
  • Pharmacokinetic studies performed in nine patients revealed that thiotepa was rapidly lost from the peritoneal cavity in a biexponential fashion with a mean t1/2 alpha of 0.26 +/- 0.08 hour and a mean t1/2 beta of 2.13 +/- 0.52 hour [22].
  • Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa [23].
  • Thiotepa-based high-dose chemotherapy with autologous stem-cell rescue in patients with recurrent or progressive CNS germ cell tumors [24].
  • METHODS: Women with newly diagnosed disease received four 2-week cycles of doxorubicin 90 mg/m2 with granulocyte colony-stimulating factor (G-CSF), followed by cyclophosphamide 6,000 mg/m2, thiotepa 500 mg/m2, and carboplatin 800 mg/m2 (CTCb) with marrow and peripheral-blood progenitor cell (PBPC) support [25].

Associations of thiotepa with other chemical compounds


Gene context of thiotepa


Analytical, diagnostic and therapeutic context of thiotepa


  1. Hematologic effects of intravesicular thiotepa therapy for bladder carcinoma. Hollister, D., Coleman, M. JAMA (1980) [Pubmed]
  2. High-dose tri-alkylator chemotherapy with autologous stem cell rescue in patients with refractory malignancies. Moormeier, J.A., Williams, S.F., Kaminer, L.S., Garner, M., Bitran, J.D. J. Natl. Cancer Inst. (1990) [Pubmed]
  3. Therapy of essential thrombocythemia with thiotepa and chlorambucil. Case, D.C. Blood (1984) [Pubmed]
  4. Glutathione-dependent biotransformation of the alkylating drug thiotepa and transport of its metabolite monoglutathionylthiotepa in human MCF-7 breast cancer cells. Cnubben, N.H., Rommens, A.J., Oudshoorn, M.J., Van Bladeren, P.J. Cancer Res. (1998) [Pubmed]
  5. Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children's Cancer Group. Finlay, J.L., Goldman, S., Wong, M.C., Cairo, M., Garvin, J., August, C., Cohen, B.H., Stanley, P., Zimmerman, R.A., Bostrom, B., Geyer, J.R., Harris, R.E., Sanders, J., Yates, A.J., Boyett, J.M., Packer, R.J. J. Clin. Oncol. (1996) [Pubmed]
  6. Experience with bacillus Calmette-Guérin in patients with superficial bladder tumors. Value of monocyte activation in intravesical bacillus Calmette-Guérin therapy. Nissenkorn, I., Lavie, G., Keisari, Y., Leib, Z., Vilcovsky, E., Servadio, C., Shachter, H. Eur. Urol. (1987) [Pubmed]
  7. Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome. Lee, J.L., Gooley, T., Bensinger, W., Schiffman, K., McDonald, G.B. Biol. Blood Marrow Transplant. (1999) [Pubmed]
  8. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. Aversa, F., Tabilio, A., Velardi, A., Cunningham, I., Terenzi, A., Falzetti, F., Ruggeri, L., Barbabietola, G., Aristei, C., Latini, P., Reisner, Y., Martelli, M.F. N. Engl. J. Med. (1998) [Pubmed]
  9. Alkylating agents and immunotoxins exert synergistic cytotoxic activity against ovarian cancer cells. Mechanism of action. Lidor, Y.J., O'Briant, K.C., Xu, F.J., Hamilton, T.C., Ozols, R.F., Bast, R.C. J. Clin. Invest. (1993) [Pubmed]
  10. Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumors. Eder, J.P., Antman, K., Elias, A., Shea, T.C., Teicher, B., Henner, W.D., Schryber, S.M., Holden, S., Finberg, R., Chritchlow, J. J. Natl. Cancer Inst. (1988) [Pubmed]
  11. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Rondelli, D., Barosi, G., Bacigalupo, A., Prchal, J.T., Popat, U., Alessandrino, E.P., Spivak, J.L., Smith, B.D., Klingemann, H.G., Fruchtman, S., Hoffman, R. Blood (2005) [Pubmed]
  12. A phase I-II study of bialkylator chemotherapy, high-dose thiotepa, and cyclophosphamide with autologous bone marrow reinfusion in patients with advanced cancer. Williams, S.F., Bitran, J.D., Kaminer, L., Westbrook, C., Jacobs, R., Ashenhurst, J., Robin, E., Purl, S., Beschorner, J., Schroeder, C. J. Clin. Oncol. (1987) [Pubmed]
  13. High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group. Dunkel, I.J., Boyett, J.M., Yates, A., Rosenblum, M., Garvin, J.H., Bostrom, B.C., Goldman, S., Sender, L.S., Gardner, S.L., Li, H., Allen, J.C., Finlay, J.L. J. Clin. Oncol. (1998) [Pubmed]
  14. Myeloablative combination chemotherapy without total body irradiation for neuroblastoma. Kushner, B.H., O'Reilly, R.J., Mandell, L.R., Gulati, S.C., LaQuaglia, M., Cheung, N.K. J. Clin. Oncol. (1991) [Pubmed]
  15. Impact of preexisting CNS involvement on the outcome of bone marrow transplantation in adult hematologic malignancies. van Besien, K., Przepiorka, D., Mehra, R., Giralt, S., Khouri, I., Gajewski, J., Andersson, B., Champlin, R. J. Clin. Oncol. (1996) [Pubmed]
  16. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. Grossman, S.A., Finkelstein, D.M., Ruckdeschel, J.C., Trump, D.L., Moynihan, T., Ettinger, D.S. J. Clin. Oncol. (1993) [Pubmed]
  17. Pharmacokinetics of intraventricular and intravenous N,N',N''-triethylenethiophosphoramide (thiotepa) in rhesus monkeys and humans. Strong, J.M., Collins, J.M., Lester, C., Poplack, D.G. Cancer Res. (1986) [Pubmed]
  18. Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid. O'Dwyer, P.J., LaCreta, F., Nash, S., Tinsley, P.W., Schilder, R., Clapper, M.L., Tew, K.D., Panting, L., Litwin, S., Comis, R.L. Cancer Res. (1991) [Pubmed]
  19. Cytotoxic, cell cycle, and chromosomal effects of methylxanthines in human tumor cells treated with alkylating agents. Fingert, H.J., Chang, J.D., Pardee, A.B. Cancer Res. (1986) [Pubmed]
  20. Evidence for enzymatic activation and oxygen involvement in cytotoxicity and antitumor activity of N,N',N''-triethylenethiophosphoramide. Teicher, B.A., Waxman, D.J., Holden, S.A., Wang, Y.Y., Clarke, L., Alvarez Sotomayor, E., Jones, S.M., Frei, E. Cancer Res. (1989) [Pubmed]
  21. Myeloid and lymphoid chimerism after T-cell-depleted bone marrow transplantation: evaluation of conditioning regimens using the polymerase chain reaction to amplify human minisatellite regions of genomic DNA. Mackinnon, S., Barnett, L., Bourhis, J.H., Black, P., Heller, G., O'Reilly, R.J. Blood (1992) [Pubmed]
  22. Phase I clinical and pharmacokinetic study of thiotepa administered intraperitoneally in patients with advanced malignancies. Wadler, S., Egorin, M.J., Zuhowski, E.G., Tortorello, L., Salva, K., Runowicz, C.D., Wiernik, P.H. J. Clin. Oncol. (1989) [Pubmed]
  23. Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. Heideman, R.L., Cole, D.E., Balis, F., Sato, J., Reaman, G.H., Packer, R.J., Singher, L.J., Ettinger, L.J., Gillespie, A., Sam, J. Cancer Res. (1989) [Pubmed]
  24. Thiotepa-based high-dose chemotherapy with autologous stem-cell rescue in patients with recurrent or progressive CNS germ cell tumors. Modak, S., Gardner, S., Dunkel, I.J., Balmaceda, C., Rosenblum, M.K., Miller, D.C., Halpern, S., Finlay, J.L. J. Clin. Oncol. (2004) [Pubmed]
  25. High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma. Ayash, L.J., Elias, A., Ibrahim, J., Schwartz, G., Wheeler, C., Reich, E., Lynch, C., Warren, D., Shapiro, C., Richardson, P., Hurd, D., Schnipper, L., Frei, E., Antman, K. J. Clin. Oncol. (1998) [Pubmed]
  26. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Elias, A.D., Ayash, L., Anderson, K.C., Hunt, M., Wheeler, C., Schwartz, G., Tepler, I., Mazanet, R., Lynch, C., Pap, S. Blood (1992) [Pubmed]
  27. Risk factors for syngeneic graft-versus-host disease after adult hematopoietic cell transplantation. Adams, K.M., Holmberg, L.A., Leisenring, W., Fefer, A., Guthrie, K.A., Tylee, T.S., McDonald, G.B., Bensinger, W.I., Nelson, J.L. Blood (2004) [Pubmed]
  28. Sensitivities of monolayers and spheroids of the human bladder cancer cell line MGH-U1 to the drugs used for intravesical chemotherapy. Knuchel, R., Hofstadter, F., Jenkins, W.E., Masters, J.R. Cancer Res. (1989) [Pubmed]
  29. Lisofylline inhibits transforming growth factor beta release and enhances trilineage hematopoietic recovery after 5-fluorouracil treatment in mice. Clarke, E., Rice, G.C., Weeks, R.S., Jenkins, N., Nelson, R., Bianco, J.A., Singer, J.W. Cancer Res. (1996) [Pubmed]
  30. CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Ramírez, J., Innocenti, F., Schuetz, E.G., Flockhart, D.A., Relling, M.V., Santucci, R., Ratain, M.J. Drug Metab. Dispos. (2004) [Pubmed]
  31. Allelic variants of the human glutathione S-transferase P1 gene confer differential cytoprotection against anticancer agents in Escherichia coli. Ishimoto, T.M., Ali-Osman, F. Pharmacogenetics (2002) [Pubmed]
  32. Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: expansion of immune effectors within the stem-cell graft and post-stem-cell infusion. Sosman, J.A., Stiff, P., Moss, S.M., Sorokin, P., Martone, B., Bayer, R., van Besien, K., Devine, S., Stock, W., Peace, D., Chen, Y., Long, C., Gustin, D., Viana, M., Hoffman, R. J. Clin. Oncol. (2001) [Pubmed]
  33. Hprt mutant frequency and molecular analysis of Hprt mutations in Fischer 344 rats treated with thiotepa. Chen, T., Aidoo, A., Mittelstaedt, R.A., Casciano, D.A., Heflich, R.H. Carcinogenesis (1999) [Pubmed]
  34. Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA. Jacobson, P.A., Green, K., Birnbaum, A., Remmel, R.P. Cancer Chemother. Pharmacol. (2002) [Pubmed]
  35. Bone marrow transplantation for peripheral T-cell lymphoma in children and adolescents. Gordon, B.G., Warkentin, P.I., Weisenburger, D.D., Vose, J.M., Sanger, W.G., Strandjord, S.E., Anderson, J.R., Verdirame, J.D., Bierman, P.J., Armitage, J.O. Blood (1992) [Pubmed]
  36. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Bensinger, W.I., Weaver, C.H., Appelbaum, F.R., Rowley, S., Demirer, T., Sanders, J., Storb, R., Buckner, C.D. Blood (1995) [Pubmed]
  37. Intracavitary chemotherapy with thiotepa in malignant pericardial effusions: an active and well-tolerated regimen. Colleoni, M., Martinelli, G., Beretta, F., Marone, C., Gallino, A., Fontana, M., Graffeo, R., Zampino, G., De Pas, T., Cipolla, G., Martinoni, C., Goldhirsch, A. J. Clin. Oncol. (1998) [Pubmed]
  38. Behavioral profiling of human transitional cell carcinoma ex vivo. Estrada, C.R., Salanga, M., Bielenberg, D.R., Harrell, W.B., Zurakowski, D., Zhu, X., Palmer, M.R., Freeman, M.R., Adam, R.M. Cancer Res. (2006) [Pubmed]
WikiGenes - Universities